Business, energy, technology, markets and global industry news from Business News Today

Humacyte Inc.

PharmaDeviceNews Humacyte Inc.
A representative image illustrating Humacyte, Inc.’s ATEV hemodialysis access program as peer-reviewed Phase 3 V007 data strengthen the company’s planned FDA filing for a potential dialysis indication.
Medical Devices & Diagnostics

ATEV beats AV fistula in Phase 3 dialysis trial as Humacyte prepares FDA filing

Humacyte’s ATEV beats AV fistula in Phase 3 dialysis access testing as peer-reviewed V007 data strengthen its planned 2026 FDA filing.

Read More